Fifteen of sixteen patients (94%) who relapsed after ide-cel infusion retained BCMA-expressing tumor cells in bone marrow, which indicates that those patients may benefit from anti-BCMA therapy. The gene discussed is TNFRSF17; the disease is neoplasm.